Transplant Burden, Late Effects, and Patient Counseling in AYA ALL Treated with Pediatric-Inspired Regimens

Dr. Curran frames the discussion around the Freyer et al. finding that AYA patients with ALL treated with non-PIRs are significantly more likely to undergo allogeneic stem cell transplant (allo-SCT) in first remission (33% versus 16% at 2 years), with associated higher patient burden and greater healthcare resource utilization. Dr. Silverman describes allo-SCT as an intensive treatment involving prolonged hospitalization, significant long-term quality-of-life implications, and frequent ongoing healthcare needs driven by complications including graft-versus-host disease (GVHD). By contrast, PIRs for AYA ALL are delivered predominantly on an outpatient basis, do not require prolonged hospitalization, and are not associated with the degree of secondary health burden seen with transplant during or after treatment.

Dr. Silverman emphasizes the pediatric oncology perspective on long-term effects, noting that drugs used in ALL PIRs are generally not associated with infertility, significant radiation exposure, endocrine dysfunction, end-organ damage, or meaningfully elevated secondary malignancy risk. These favorable late-effect profiles contrast sharply with transplant preparative regimens, particularly those incorporating total body irradiation. He reassures patients that while short-term side effects during therapy are real, significant long-term late effects are uncommon with modern PIR-based ALL treatment, and the field has progressively refined regimens to further minimize long-term harm.

Dr. Curran adds that she actively counsels AYA patients about underestimated transplant toxicities while also being transparent about PIR treatment burden. The primary quality-of-life challenge with PIRs is treatment duration and the frequency of clinic visits, sometimes several times per week, over approximately 3 years. Peripheral neuropathy is a specific adverse effect she monitors closely, using a practical patient-centered benchmark, asking whether patients can still text, as a functional gauge for neuropathy severity and a guide for dose modification decisions.

Dr. Silverman closes by challenging the intuitive patient assumption that transplant, as a shorter and more defined intervention, must therefore be easier. Post-transplant isolation precautions are substantially disruptive to daily life, and patients who develop chronic GVHD may face prolonged immunosuppression, extended isolation requirements, and debilitating neuropathy that can persist for years. The seemingly straightforward "do it and done" framing of transplant versus a 3-year chemotherapy course obscures the full downstream burden that patients and families should understand before treatment decisions are made.